Last reviewed · How we verify
Ethinylestradiol / Dienogest
Ethinylestradiol and dienogest work together as a combined oral contraceptive, suppressing ovulation through hormonal feedback on the hypothalamic-pituitary-ovarian axis.
Ethinylestradiol and dienogest work together as a combined oral contraceptive, suppressing ovulation through hormonal feedback on the hypothalamic-pituitary-ovarian axis. Used for Contraception, Endometriosis.
At a glance
| Generic name | Ethinylestradiol / Dienogest |
|---|---|
| Sponsor | University of Palermo |
| Drug class | Combined oral contraceptive |
| Target | Estrogen receptor, progesterone receptor |
| Modality | Small molecule |
| Therapeutic area | Contraception, Gynecology |
| Phase | FDA-approved |
Mechanism of action
Ethinylestradiol is a synthetic estrogen that inhibits follicle-stimulating hormone (FSH) secretion, while dienogest is a progestin that suppresses luteinizing hormone (LH) and increases cervical mucus viscosity. Together, they prevent ovulation and alter the endometrial environment to reduce pregnancy risk. This combination is also used to treat endometriosis due to dienogest's anti-inflammatory and anti-proliferative effects on ectopic endometrial tissue.
Approved indications
- Contraception
- Endometriosis
Common side effects
- Nausea
- Headache
- Breast tenderness
- Breakthrough bleeding
- Mood changes
- Venous thromboembolism
Key clinical trials
- "Quick-starting" of a Quadriphasic Contraceptive Pills, 1 - 3 mg Estradiol Valerate/ 2 - 3 mg Dienogest VS 20 mcg Ethinylestradiol/75 mcg Gestodene Focusing on Ovulation Inhibition (NA)
- The Progression From Dysmenorrhoea to Chronic Pelvic Pain
- Comparing the Safety and Efficacy in the Use of Hormonal Therapy on Endometriosis Patients After Conservative Surgery (PHASE3)
- To Compare SH T00658ID Over Ortho Tri-Cyclen Lo (US/Canada) (PHASE3)
- Role of Medical Treatment in Endometriosis Patients Undergoing ICSI (NA)
- Gonadotropin-releasing Hormone (GnRH) Downregulation Versus Oral Anticonception Prior to ART in Postoperative Endometriosis Patients (NA)
- The Use of Ethinylestradiol/Dienogest in Random Start Rapid Endometrial Preparation (PHASE4)
- The Use of Drospirenone/Estetrol, Nomegestrol Acetate/Estradiol and Ethinylestradiol/Dienogest in Random Start Rapid Endometrial Preparation (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ethinylestradiol / Dienogest CI brief — competitive landscape report
- Ethinylestradiol / Dienogest updates RSS · CI watch RSS
- University of Palermo portfolio CI